Hutchinson Capital Management CA Sells 1,306 Shares of Pfizer Inc. (NYSE:PFE)

Hutchinson Capital Management CA lowered its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 3.5% during the fourth quarter, Holdings Channel reports. The fund owned 35,820 shares of the biopharmaceutical company’s stock after selling 1,306 shares during the period. Hutchinson Capital Management CA’s holdings in Pfizer were worth $1,031,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc bought a new position in Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter valued at about $34,000. VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.00.

View Our Latest Analysis on Pfizer

Pfizer Stock Down 0.6 %

PFE traded down $0.16 during trading hours on Friday, reaching $28.02. The company’s stock had a trading volume of 25,819,661 shares, compared to its average volume of 44,708,136. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average is $26.97 and its 200-day moving average is $28.12. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.23 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.